Show simple item record

dc.contributor.authorHallstensen, Randi
dc.contributor.authorBergseth, Grete
dc.contributor.authorFoss, Stian
dc.contributor.authorJæger, Steinar
dc.contributor.authorGedde-Dahl, Thobias
dc.contributor.authorHolt, jan
dc.contributor.authorChristiansen, Dorte
dc.contributor.authorLau, Corinna
dc.contributor.authorBrekke, Ole Lars
dc.contributor.authorArmstrong, Elina
dc.contributor.authorStefanovic, Vedran
dc.contributor.authorAndersen, Jan Terje
dc.contributor.authorSandlie, Inger
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2016-03-17T11:51:05Z
dc.date.available2016-03-17T11:51:05Z
dc.date.issued2015-11-13
dc.description.abstractEculizumab is a humanized IgG2/4 chimeric anti-complement C5 antibody used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome. The aim of this study was to evaluate whether or not the complement activity in newborns from pregnant women who receive eculizumab is impaired. A novel eculizumab-C5 complex (E-C5) specific assay was developed and revealed that two newborns carried only 6–7% of the E-C5 detected in their eculizumab-treated PNH mothers. Serum from the pregnant women completely lacked terminal complement pathway activity, whereas the complement activity in the serum of the newborns was completely normal. Data from the pregnant women and their newborns were compared with that of healthy age-matched female controls and healthy newborns, as well as a non-treated pregnant woman with PNH and her newborn. These all showed normal complement activity without detectable E-C5 complexes. Furthermore, absence of eculizumab or E-C5 in the newborn could not be explained by lack of eculizumab binding to the neonatal Fc receptor (FcRn), as eculizumab bound strongly to the receptor in vitro. In conclusion, despite binding to FcRn neither eculizumab nor E-C5 accumulates in fetal plasma, and eculizumab treatment during pregnancy does not impair the complement function in the newborn.en_US
dc.descriptionPublished version also available at <a href=http://dx.doi.org/10.1016/j.imbio.2014.11.003>http://dx.doi.org/10.1016/j.imbio.2014.11.003</a>en_US
dc.identifier.citationImmunobiology 2015, 220(4):452-459en_US
dc.identifier.cristinIDFRIDAID 1182182
dc.identifier.doi10.1016/j.imbio.2014.11.003
dc.identifier.issn0171-2985
dc.identifier.urihttps://hdl.handle.net/10037/9008
dc.identifier.urnURN:NBN:no-uit_munin_8574
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.projectIDNorges forskningsråd: 223255en_US
dc.rights.accessRightsopenAccess
dc.subjectComplementen_US
dc.subjectTherapyen_US
dc.subjectPlacentaen_US
dc.subjectEculizumaben_US
dc.subjectParoxysmal nocturnal hemoglobinuriaen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.titleEculizumab treatment during pregnancy does not affect the complement system activity of the newbornen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record